MyMetabolon Login
© 2021 Metabolon, Inc. All rights reserved.
Metabolon Metabolon
  • Metabolomics
    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Quality Assurance
    • Setting the Standard: The 4Cs
    • Our Latest Insights
  • Solutions
    • Column 1
      • Products & Services
        • Global Metabolomics
        • Lipidomics
        • Targeted Assays
        • Microbiome
        • Study Design & Consulting
        • Sample Preparation & Handling
        • Study Success Sample Handling Kit
        • Reporting & Interpretation
        • Bioinformatics
        • MyMetabolon Client Portal
    • Column 2
      • By Research & Development Phase
        • Discovery & Target Selection
        • Lead Candidate Selection
        • Preclinical
        • Clinical Development
        • Manufacturing & Bioprocessing
    • Column 3
      • By Therapeutic Area
        • Cardiovascular Disease
        • COVID-19
        • Diabetes
        • Gastrointestinal
        • Liver Disease
        • Neuroscience
        • Oncology
        • Renal & Urological Disorders
        • Respiratory Disorders
    • Column 4
      • By Sector
        • Academic
        • Agriculture
        • Biotech / Pharmaceutical
        • Precision Medicine
        • Nutrition
        • Personal Care & Cosmetics
        • Population Health
        • Veterinary & Animal Health
  • Insights
    • Our Latest Insights
    • Blog
    • News & Events
    • Publications
  • Resources
    • Resource Library
    • Client Stories
    • COVID-19
    • Publications
  • Company
    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
MyMetabolon
Demo Our Data
Metabolon
Demo Our Data
karl-2

Karl Bradshaw, Ph.D.

Vice President, Corporate Development

Karl drives Metabolon’s growth strategy by identifying, evaluating, and executing partnering opportunities that align with the company’s strategic goals and technical expertise.

About

Karl has a deep understanding of global healthcare sector trends for drugs and devices, along with extensive financial analysis experience. Before joining Metabolon, he was a member of AstraZeneca’s corporate development team, responsible for business strategy, including mergers and acquisitions, divestitures, and investments. He honed his financial analysis capabilities at Morgan Stanley as a Vice President in Equity Research, covering the European biotechnology and medical device sectors. Karl earned his Ph.D. in Neuroscience from University College London and holds an MPhil in Bioscience Enterprise from Cambridge University.

Enlighten your research,
accelerate your discovery.

Demo Our Data
or Talk With an Expert

Metabolomics

  • About Metabolomics
  • Our Process
  • Technology & Knowledgebase
  • Quality Assurance
  • Setting the Standard: The 4Cs
  • Insights & Discoveries

Solutions

  • Products & Services
  • By Research & Development Phase
  • By Therapeutic Area
  • By Sector

Insights

  • Our Latest Insights
  • Blog
  • News & Events
  • Publications

Resources

  • Resource Library
  • Client Stories
  • COVID-19

Company

  • About Us
  • Working With Us (FAQ)
  • Leadership
  • Careers
  • Strategic Partnering
  • News & Events
  • Contact Us
Metabolon - Logo - Enlightening Life

Metabolon provides actionable biological insights to answer the toughest questions in life sciences research and drug development.

© 2022 Metabolon, Inc. All rights reserved. Privacy & Terms

in